Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 58Carcinoma, Non-Small-Cell Lung 36Urinary Bladder Neoplasms 33Neoplasm Metastasis 20Lung Neoplasms 20Ovarian Neoplasms 19Lymphoma, Large B-Cell, Diffuse 18Cholangiocarcinoma 15Neoplasms 14Nasopharyngeal Carcinoma 14Biliary Tract Neoplasms 14Triple Negative Breast Neoplasms 13Colorectal Neoplasms 12Breast Neoplasms 12Carcinoma, Transitional Cell 11Non-Muscle Invasive Bladder Neoplasms 10Fallopian Tube Neoplasms 10Recurrence 9Gallbladder Neoplasms 8Sarcoma 6Parkinson Disease 4, Autosomal Dominant Lewy Body 6Bile Duct Neoplasms 6Uterine Cervical Neoplasms 5Osteosarcoma 5Lymphoma, Non-Hodgkin 5Lymphoma 5Hodgkin Disease 5Endometrial Neoplasms 5Melanoma 4Gastrointestinal Neoplasms 4

Interventions

Gemcitabine 2Taxes 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Metastatic Pancreatic Ductal Adenocarcinoma × Gemcitabine × 90 days × Clear all
NCT06904378 2026-05-19

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma

Washington University School of Medicine

Phase 1/2 Recruiting
61 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

NCT06646055 2026-03-09

AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer

Akeso

Phase 1/2 Active not recruiting
110 enrolled
Gastrointestinal

Metastatic Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡